Announcements, milestones, partnerships, and presentations from our team — straight from the labs and the floor.
Biocom California’s LifeLines newsletter features GeneFab’s CEO on integrating synthetic biology with GMP manufacturing and building platforms for in vivo cell and gene therapies.
A strategic CDMO collaboration that strengthens Axiom's development infrastructure as the company prepares to advance its therapeutic pipeline.
Additional growth equity led by a Taiwanese strategic investor consortium, with participation from Celadon Partners — plus the appointment of Drew Johnston as President and COO and Vadim Eristavi as Chief Quality Officer.
Pre-validated synthetic promoters and drug-induced switches enable safer, more precise, and clinically translatable cell and gene therapies.
Advancing cell therapy with process intensification.
GeneFab has partnered with RegCell, a biotech company advancing regulatory T cell (Treg) therapies for autoimmune diseases, to bring their lead program into U.S. clinical trials.
For the treatment of relapsed or refractory hematologic malignancies including acute myeloid leukemia.
Two poster presentations at the 27th Annual Meeting, May 7–11, 2024 in Baltimore, MD.
GeneFab launches as a cell and gene therapy CRDMO led by Philip Lee, PhD, combining synthetic biology design with advanced cGMP manufacturing in the San Francisco Bay Area.
GeneFab's cGMP facility in the San Francisco Bay Area has available capacity to support new customers with complex cell and gene therapy manufacturing.
For press inquiries or to be added to our distribution list, reach out — we'll keep you posted.
